Phase III trial of Respimat (tiotropium) shows efficacy in asthma- Boehringer
Boehringer announced new study results from the Phase III CanoTinA-asthma trial that showed adding Respimat (tiotropium) to maintenance asthma therapy, in children aged 6-11, significantly improved lung function, as measured by forced expiratory volume in one second measured from 0 to 3 hours after dosing (FEV1(0-3h)), compared to placebo. The trial investigated tiotropium RESPIMAT as an add-on therapy for children who were already taking an inhaled corticosteroid (ICS), or an ICS combined with other maintenance therapy. In this study, the safety and tolerability of tiotropium RESPIMAT were shown to be comparable to placebo.
A new pooled analysis from four studies, VivaTinA-asthma, RubaTinA-asthma, PensieTinA-asthma and CanoTinA-asthma also presented at ERS showed adding tiotropium RESPIMAT to maintenance therapy for children aged 6-17 years has a comparable safety profile to placebo. In addition, this analysis showed tiotropium RESPIMAT improved peak expiratory flow (PEF), a common measure of asthma control, in participants aged 6-17 years. A further analysis presented from the NinoTinA-asthma trial showed the safety profile of adding tiotropium RESPIMAT to maintenance therapy among children aged 1-5 is consistent with that found in older children and adults. These findings were presented at the European Respiratory Society (ERS) International Congress 2016 in London.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins